Why the study?
Does a single subcutaneous dose of recombinant human IGF-I alter serum concentrations of IGF binding proteins and IGFs in adolescents with insulin-dependent diabetes mellitus?
Does a single subcutaneous dose of recombinant human IGF-I alter serum concentrations of IGF binding proteins and IGFs in adolescents with insulin-dependent diabetes mellitus?
A single subcutaneous dose of recombinant human IGF-I in adolescents with IDDM increases IGFBP-3 levels despite a slight fall in ALS, likely due to the relative stability of the ALS/IGFBP-3 complex when bound to IGF-I.
No takes yet. Share an insight, caveat, or question.
Single rhIGF-I dose may alter IGF axis in IDDM adolescents; leaves open effects on growth or metabolism.
Cheetham et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: